Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Blastokinin; CC10; CC16; CCSP; CG 100; CG 367; CG201; CG459; Clara cell 10 kDa protein; Claragen; PCB-binding protein; Recombinant human CC10 protein; Recombinant human Clara cell 10 kDa protein; Recombinant human secretoglobin 1A1; rhCC10; SCGB1A1; Urine protein-1

Latest Information Update: 13 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Brigham and Womens Hospital; Therabron Therapeutics; Tufts-New England Medical Center
  • Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Bronchiolitis obliterans
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia
  • Phase I/II Sinusitis
  • Preclinical Bronchiolitis obliterans
  • No development reported Acute lung injury; Asthma; Burns; Chronic obstructive pulmonary disease; Influenza virus infections; Pneumonia; Respiratory distress syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top